Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | FDPS | P14324 | 16/20 | 0.45 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2532821 | 0.92 | CYP11B1 (0.50) | CYP11B1CYP11B2FDPSBTN3A1PDE3A | |
| SCHEMBL1083518 | 0.81 | FDPS (0.49) | FDPSBTN3A1PDE3AGGPS1 | |
| SCHEMBL2532378 | 0.80 | FDPS (0.44) | CYP11B1CYP11B2FDPSBTN3A1GGPS1 | |
| SCHEMBL1157059 | 0.78 | GGPS1 (0.47) | CYP11B1CYP11B2FDPSBTN3A1GGPS1 | |
| SCHEMBL1028191 | 0.77 | FDPS (0.51) | FDPSBTN3A1PDE3AGGPS1 | |
| SCHEMBL1027186 | 0.76 | FDPS (0.50) | FDPSBTN3A1PDE3AGGPS1 | |
| SCHEMBL1029369 | 0.76 | FDPS (0.50) | FDPSBTN3A1PDE3AGGPS1 | |
| SCHEMBL2532831 | 0.72 | FDPS (0.43) | CYP11B1CYP11B2FDPSBTN3A1PDE3A | |
| SCHEMBL1028197 | 0.71 | FDPS (0.58) | FDPSBTN3A1PDE3AGGPS1 | |
| SCHEMBL2536376 | 0.71 | FDPS (0.45) | FDPSBTN3A1GGPS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382223-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | Novartis AG (CH) | 2011-11-02 | — | — | EP | disclosed |
| US-20110257131-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257131-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
| US-20110257131-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | NOVARTIS AG (CH) | 2011-10-20 | — | — | US | disclosed |
| WO-2010076258-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | NOVARTIS AG (CH) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257131-A1 | PHENYLALKYL-IMIDAZOLE-BISPHOSPHONATE COMPOUNDS | PTEN, INPP5D, PPIP5K2 | CYP11B1 2146/4885CYP11B2 2431/4885FDPS 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.